Phase 1b Study of Elranatamab and Iberdomide Combination for Relapsed or Refractory Multiple Myeloma

What this Trial Is About

Researchers are evaluating the safety and tolerability of elranatamab combined with iberdomide in patients with relapsed or refractory multiple myeloma, a cancer of plasma cells. This phase 1b study includes two parts the first part assesses safety and tolerability, while the second part determines the appropriate dose of this combination for patients whose disease has returned or not responded to prior treatments. Participants receive elranatamab as a shot under the skin and take iberdomide by mouth once daily for 21 days in each 28-day treatment cycle. The study includes a non-randomized dose escalation phase and a randomized dose assignment phase. Treatment continues until disease progression, unacceptable side effects, or participant choice to stop. Both parts of the study monitor participants closely for treatment effects. During the study, participants will have regular assessments including monitoring for side effects, laboratory tests, and evaluations of disease response and progression. The main outcomes include the number of participants with dose-limiting toxicities and adverse events related to treatment, measured during the first cycle and up to 90 days after the last dose. Long-term measures such as response rates, survival times, and drug concentrations will be followed for up to two years. This information will help understand treatment safety and appropriate dosing.

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)